Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Apr

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer (1)

Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are Reassuring Say Researchers

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods

Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma